CYP3A5*3A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia

Clinica Chimica Acta

Volumn 398, Issue 1-2, 2008, Pages 15-20

  Willrich, Maria Alice V ^a   Hirata, Mario H ^a   Genvigir, Fabiana D V ^a   Arazi, Simone S ^a   Rebecchi, Ivanise M M ^a   Rodrigues, Alice C ^a   Bernik, Marcia M S ^a   Dorea, Egidio L ^a   Bertolami, Marcelo C ^b   Faludi, André A ^b   Hirata, Rosario D C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

Author keywords

CYP3A5; Hypercholesterolemia; Lipid lowering response; Pharmacogenomics; Statins

Indexed keywords

ATORVASTATIN; CHOLESTEROL; CYTOCHROME P450 3A5; GENOMIC DNA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; DNA; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRIMER DNA; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; BIOTRANSFORMATION; DNA SEQUENCE; ETHNIC DIFFERENCE; FEMALE; GENE FREQUENCY; HETEROZYGOTE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; BLOOD; BODY MASS; BRAZIL; GENETICS; GENOTYPE; MIDDLE AGED; NEGRO; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; ALLELES; BODY MASS INDEX; BRAZIL; CHOLESTEROL, LDL; CYTOCHROME P-450 CYP3A; DNA; DNA PRIMERS; FEMALE; GENE FREQUENCY; GENOTYPE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PYRROLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 54049115013     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2008.07.032     Document Type: Article

References (38)

1. Vaughan C.J., and Gotto Jr. A.M. Update on statins: 2003. Circulation 110 (2004) 886-892
2. Brown M.S., and Goldstein J.L. Lowering plasma cholesterol by raising LDL receptors. 1981. Atheroscler Suppl 5 (2004) 57-59
3. Stein E.A. Managing dyslipidemia in the high-risk patient. Am J Cardiol 89 (2002) 50C-7C
4. Bellosta S., Paoletti R., and Corsini A. Safety of statins. Circulation 109S3 (2004) 50-57
5. Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 42 (2003) 1141-1160
6. Bogman K., Peyer A.K., Torok M., Kusters E., and Drewe J. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol 132 (2001) 1183-1192
7. Wojnowski L. Genetics of the variable expression of CYP3A in humans. Ther Drug Monit 26 (2004) 192-199
8. Siest G., Marteau J.B., Maumus S., Berrahmoune H., Jeannesson E., Samara A., et al. Pharmacogenomics and cardiovascular drugs: need for integrated biological system with phenotypes and proteomic markers. Eur J Pharmacol 527 (2005) 1-22
9. Rodrigues A.C., Hirata M.H., and Hirata R.D. The genetic determinants of atorvastatin response. Curr Opin Mol Ther 9 (2007) 545-553
10. Hustert E., Haberl M., Burk O., Wolbold R., He Y.Q., Klein K., et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11 (2001) 773-779
11. Kuehl P., Zhang J., Lin Y., Lamba J., Assem M., Schuetz J., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27 (2001) 383-391
12. Fukuen S., Fukuda T., Maune H., Ikenaga Y., Yamamoto I., Inaba T., et al. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics 12 (2002) 331-334
13. Lamba J.K., Lin Y.S., Schuetz E.G., and Thummel K.E. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54 (2002) 1271-1294
14. Lee S.J., Usmani K.A., Chanas B., Ghanayem B., Xi T., Hodgson E., et al. Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics 13 (2003) 461-472
15. Xie H.G., Wood A.J., Kim R.B., Stein C.M., and Wilkinson G.R. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5 (2004) 243-272
16. Kivisto K.T., Niemi M., Schaeffeler E., Pitkala K., Tilvis R., Fromm M.F., et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 14 (2004) 523-525
17. Wilke R.A., Moore J.H., and Burmester J.K. Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenet Genomics 15 (2005) 415-421
18. Fiegenbaum M., da Silveira F.R., Van der Sand C.R., Van der Sand L.C., Ferreira M.E., Pires R.C., et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther 78 (2005) 551-558
19. Chasman D.I., Posada D., Subrahmanyan L., Cook N.R., Stanton Jr. V.P., and Ridker P.M. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291 (2004) 2821-2827
20. Gervasini G., Vizcaino S., Gasiba C., Carrillo J.A., and Benitez J. Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and other Caucasian populations. Ther Drug Monit 27 6 (2005) 819-821
21. Rodrigues A.C., Rebecchi I.M., Bertolami M.C., Faludi A.A., Hirata M.H., and Hirata R.D. High baseline serum total and LDL cholesterol levels are associated with MDR1 haplotypes in Brazilian hypercholesterolemic individuals of European descent. Braz J Med Biol Res 38 (2005) 1389-1397
22. Sorkin S.C., Forestiero F.J., Hirata M.H., Guzman E.C., Cavalli S.A., Bertolami M.C., et al. APOA1 polymorphisms are associated with variations in serum triglyceride concentrations in hypercholesterolemic individuals. Clin Chem Lab Med 43 (2005) 1339-1345
23. Genvigir F.D., Soares S.A., Hirata M.H., Willrich M.A., Arazi S.S., Rebecchi I.M., et al. Effects of ABCA1 SNPs, including the C-105T novel variant, on serum lipids of Brazilian individuals. Clin Chim Acta 389 (2008) 79-86
24. Chahoud G., Aude Y.W., and Mehta J.L. Dietary recommendations in the prevention and treatment of coronary heart disease: do we have the ideal diet yet?. Am J Cardiol 94 (2004) 1260-1267
25. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
26. Salazar L.A., Hirata M.H., Cavalli S.A., Machado M.O., and Hirata R.D. Optimized procedure for DNA isolation from fresh and cryopreserved clotted human blood useful in clinical molecular testing. Clin Chem 44 (1998) 1748-1750
27. Yoo J., Seo B., and Kim Y. SNPAnalyzer: a web-based integrated workbench for single-nucleotide polymorphism analysis. Nucleic Acids Res 33 (2005) W483-W488
28. van Schaik R.H., van der Heiden I.P., van den Anker J.N., and Lindemans J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 48 (2002) 1668-1671
29. Suarez-Kurtz G., Perini J.A., Bastos-Rodrigues L., Pena S.D.J., and Struchiner C. Impact of population admixture on the distribution of the CYP3A4*3 polymorphism. Pharmacogenomics 8 10 (2007) 1229-1306
30. Lee S.J., and Goldstein J.A. Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests. Pharmacogenomics 6 (2005) 357-371
31. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 19 1 (2005) 117-125
32. Asztalos B.F. High density lipoprotein metabolism and progression of atherosclerosis: new insights from the HDL Atherosclerosis Treatment Study. Curr Opinion Cardiol 19 (2004) 385-391
33. Schmitz G., and Drobnik W. Pharmacogenomics and pharmacogenetics of cholesterol-lowering therapy. Clin Chem Lab Med 41 4 (2003) 581-589
34. Simon J.A., Lin F., Hulley S.B., Blanche P.J., Waters D., Shiboski S., et al. Phenotypic precistors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study. Am J Cardiol 97 6 (2006) 843-850
35. Givens R.C., Lin Y.S., Dowling A.L., Thummel K.E., Lamba J.K., Schuetz E.G., et al. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol 95 (2003) 1297-1300
36. Wilke R.A., Reif D.M., and Moore J.H. Combinatorial pharmacogenetics. Nat Rev Drug Discov 4 (2005) 911-918
37. Ho H., Pinto A., Hall S.D., Flockhart D.A., Li L., Skaar T.C., et al. Association between the CYP3A5 genotype and blood pressure. Hypertension 4 5 (2005) 294-298
38. IBGE - Instituto Brasileiro de Geografia e Estatística, http://www.ibge.gov.br/home/estatistica/populacao/censo2000.